[go: up one dir, main page]

WO1998040478A3 - Antisense inhibition of human stat-6 - Google Patents

Antisense inhibition of human stat-6 Download PDF

Info

Publication number
WO1998040478A3
WO1998040478A3 PCT/EP1998/001400 EP9801400W WO9840478A3 WO 1998040478 A3 WO1998040478 A3 WO 1998040478A3 EP 9801400 W EP9801400 W EP 9801400W WO 9840478 A3 WO9840478 A3 WO 9840478A3
Authority
WO
WIPO (PCT)
Prior art keywords
antisense inhibition
human stat
stat
human
oligonucleotide
Prior art date
Application number
PCT/EP1998/001400
Other languages
French (fr)
Other versions
WO1998040478A2 (en
Inventor
Paul Leslie Nicklin
Sandra Jane Hill
Judith Ann Phillips
Helena Catharina Herlaar
Brent Graham
Original Assignee
Novartis Ag
Novartis Erfind Verwalt Gmbh
Paul Leslie Nicklin
Sandra Jane Hill
Judith Ann Phillips
Helena Catharina Herlaar
Brent Graham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Erfind Verwalt Gmbh, Paul Leslie Nicklin, Sandra Jane Hill, Judith Ann Phillips, Helena Catharina Herlaar, Brent Graham filed Critical Novartis Ag
Priority to AU69208/98A priority Critical patent/AU6920898A/en
Publication of WO1998040478A2 publication Critical patent/WO1998040478A2/en
Publication of WO1998040478A3 publication Critical patent/WO1998040478A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

An oligonucleotide having 10 to 30 nucleotide units which is complementary to at least part of mRNA encoding human Stat-6 and is capable of inhibiting expression of Stat-6.
PCT/EP1998/001400 1997-03-13 1998-03-11 Antisense inhibition of human stat-6 WO1998040478A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU69208/98A AU6920898A (en) 1997-03-13 1998-03-11 Antisense inhibition of human stat-6

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9705212.0 1997-03-13
GBGB9705212.0A GB9705212D0 (en) 1997-03-13 1997-03-13 Chemical compounds

Publications (2)

Publication Number Publication Date
WO1998040478A2 WO1998040478A2 (en) 1998-09-17
WO1998040478A3 true WO1998040478A3 (en) 1998-12-03

Family

ID=10809179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/001400 WO1998040478A2 (en) 1997-03-13 1998-03-11 Antisense inhibition of human stat-6

Country Status (3)

Country Link
AU (1) AU6920898A (en)
GB (1) GB9705212D0 (en)
WO (1) WO1998040478A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115634A1 (en) 2002-12-11 2004-06-17 Isis Pharmaceuticals, Inc. Modulation of stat 6 expression
GB0404209D0 (en) 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
DE102004026309A1 (en) * 2004-05-26 2005-12-29 Haarlems Allergenen Laboratorium B.V. Pharamceutical composition for the treatment of allergic diseases, pathological pathway changes and cancer by modulation of Stat6 gene expression
US20060258610A1 (en) * 2005-05-12 2006-11-16 Isis Pharmaceuticals, Inc. Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
JP2023506768A (en) 2019-12-12 2023-02-20 ティン セラピューティックス エルエルシー Compositions and methods for prevention and treatment of hearing loss

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002023A1 (en) * 1995-06-30 1997-01-23 Smithkline Beecham Corporation USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002023A1 (en) * 1995-06-30 1997-01-23 Smithkline Beecham Corporation USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALTMANN K H ET AL: "SECOND-GENERATION ANTISENSE OLIGONUCLEOTIDES: STRUCTURE-ACTIVITY RELATIONSHIPS AND THE DESIGN OF IMPROVED SIGNAL-TRANSDUCTION INHIBITORS", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 24, no. 3, August 1996 (1996-08-01), pages 630 - 637, XP000671118 *
NICKLIN P L ET AL: "Preclinical profiling of modified oligonucleotides: Anticoagulation and pharmacokinetic properties", NUCLEOSIDES & NUCLEOTIDES, (JUL 1997) VOL. 16, NO. 7-9, PP. 1145-1153., XP002076413 *
NYCE, J. & METZGER, J.: "DNA antisense therapy for asthma in an animal model", NATURE., vol. 385, 20 February 1997 (1997-02-20), LONDON GB, pages 721 - 725, XP002076415 *
SHIMODA, K. ET AL.: "Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene", NATURE., vol. 380, 18 April 1996 (1996-04-18), LONDON GB, pages 630 - 633, XP002076414 *

Also Published As

Publication number Publication date
WO1998040478A2 (en) 1998-09-17
GB9705212D0 (en) 1997-04-30
AU6920898A (en) 1998-09-29

Similar Documents

Publication Publication Date Title
PT731835E (en) OLIGONUCLEOTIDOS ANTI-SENSE POSSESSING ACTIVITY INHIBITOR OF TUMORIGENICITY
HUP0103571A3 (en) Characterisation of gene function using double stranded rna inhibition
AU6255896A (en) Triplex-forming antisense oligonucleotides having abasic lin kers targeting nucleic acids comprising mixed sequences of p urines and pyrimidines
IL128124A0 (en) Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
GB9514437D0 (en) Inhibition of gene expression
AU2002213002A1 (en) Antisense inhibition of caspase 6 expression
EP1222309A4 (en) Human rnase h and oligonucleotide compositions thereof
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
EP0975649A4 (en) RNASE L ACTIVATORS AND ANTISENSE OLIGONUCLEOTIDES THAT CAN EFFECTIVELY TREAT MALIGNANT CONDITIONS EXPRESSING TELOMERASE
CA2132424A1 (en) Antisense oligonucleotide inhibition of papillomavirus
EP0881914A4 (en)
EP0863911A4 (en) ANTISENSE OLIGONUCLEOTIDE MODULATION OF raf GENE EXPRESSION
EP0668144A3 (en) Use of glow discharge treatment to promote adhesion of aqueous coats to substrate.
ZA965342B (en) Beta-xylosidase nucleotide sequence encoding it and use thereof
WO1998040478A3 (en) Antisense inhibition of human stat-6
EP0950060A4 (en) Antisense inhibition of human adhesion molecules
FI951601A0 (en) Antisense oligonucleotide inhibition of rasgene
AU3729493A (en) Cyclobutyl antisense oligonucleotides, methods of making and use thereof
AU1124197A (en) Compositions and methods of developing oligonucleotides and oligonucleotide analogs having antiviral activity
GB9612442D0 (en) Biodegradation of metal cyanides
HUP0100044A1 (en) Modified antisense nucleotides complementary to a section of the human ha-ras gene
WO2000055314A3 (en) Inhibitors of endothelin-1 synthesis
MXPA02003360A (en) Transacylases of the paclitaxel biosynthetic pathway.
AU3255897A (en) Inhibition of hiv-1 replication by antisense rna expression
EP0691853A4 (en) ANTISENSE OLIGOS WHICH INTERFERE WITH mRNA CAP ACTIVITY AND INHIBIT TRANSLATION

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998539216

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA